XmAb® Antibody Therapeutics Antibodies by Design™: May 2019 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and results of clinical trial ...

Novartis AG NVS on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with Hb levels ≥10g/dL who switched from anti-C5 therapies (eculizumab or ravulizumab).The company released topline data in December 2024.What Happened: PNH is a rare complement-mediated blood disorder. People with PNH have an acquired mutation in some of their hematopoietic ste ...

AstraZeneca (AZN) stock has declined 6.4% in the past three months.Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market uncertainties and a volatile macroeconomic environment.The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets. Though the massive tariffs imposed by the United States and China are now on a pause, it is only a temporary suspension, and no ...

Rallybio Corporation (RLYB) 2025 Conference May 07, 2025 12:00 PM ET Speaker0 BUCELL actually had like a commentary in New England Journal like last week or two weeks ago, which is interesting. Speaker1 I didn't see that on FNAIT or Yeah. I'll have to dig one out. I would say it's bit of a bad memory at the moment, so it's still post traumatic stress. Speaker0 Good afternoon, I guess, everybody. John Wallabin, senior analyst here at Citizens, and welcome to day one of our Life Sciences Conference. Pleased t ...

Summary of Dianthus Therapeutics Conference Call Company Overview - **Company**: Dianthus Therapeutics - **Focus**: Development of DNTH103, a classical pathway inhibitor targeting activated C1S protein for treating classical pathway-driven diseases [4][5] Key Points and Arguments Product Development and Pipeline - **DNTH103**: A highly potent classical pathway inhibitor designed for self-administration via an auto-injector, with dosing every two weeks [4][5] - **Upcoming Catalysts**: - Phase II results for Myasthenia Gravis (MG) expected in September 2023 [5][6] - Phase II trial for Multifocal Motor Neuropathy (MMN) results anticipated in the second half of 2026 [6] - Phase III trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with interim analysis also in the second half of 2026 [6] Efficacy and Safety - **Efficacy Goals**: Aim for efficacy comparable to C5 inhibitors (e.g., Ultomiris) with a target improvement of 1.6 to 2.1 on the MG Activities of Daily Living (ADL) scale [8][26] - **Safety Profile**: Targeting a clean safety label without box warnings, similar to existing C1S inhibitors [9][63] - **Dosing Confidence**: Confidence in achieving efficacy with a 300 mg dose every two weeks, significantly above the IC90 threshold [12][14] Market Potential - **Market Size**: Potential for a multi-billion dollar blockbuster, not only in MG but also in CIDP and MMN [38] - **Competitive Landscape**: Positioning as a first-line biologic treatment for MG, competing against existing therapies like IVIG and FcRn inhibitors [34][46] Clinical Trial Design - **Phase II Trial for MG**: Largest trial conducted in MG, designed primarily for safety with secondary efficacy endpoints [25][30] - **CIDP and MMN Trials**: Following similar designs to successful trials by competitors, focusing on classical pathway inhibition [51][53] Future Indications and Expansion - **Exploration of New Indications**: Ongoing work to identify additional indications that meet scientific and commercial viability criteria [61] Important but Overlooked Content - **Cash Position**: Dianthus has over $330 million in cash, providing a runway until the second half of 2027, sufficient to support upcoming clinical trials [65] - **In Vitro Studies**: Conducted experiments showing that DNTH103 can effectively kill encapsulated bacteria, supporting its safety profile [63] - **Investor Sentiment**: Emphasis on the importance of upcoming data releases and the potential impact on investor confidence and market perception [60][66] This summary encapsulates the critical aspects of the conference call, highlighting the company's strategic direction, product pipeline, and market positioning.

AstraZeneca’s (AZN) first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.10. Core earnings of $2.49 per share rose 21% year over year on a reported basis as well as at constant exchange rates (CER).Total revenues of $13.59 billion rose 7% on a reported basis and 10% at CER, driven by higher product sales and alliance revenues from partnered medicines. However, the metric missed the Zacks Consensus Estimate of $13.68 billion. (Find the latest E ...

Dianthus Therapeutics (DNTH) Conference February 06, 2025 09:00 AM ET Company Participants Marino Garcia - President, CEO, Secretary & Director Conference Call Participants Yatin Suneja - Biotechnology Research Analyst Yatin Suneja Good morning, everyone. My name is Yatin Suneja, one of the biotech analysts here at Guggenheim. Welcome to our SMITCAP Biotech Conference. It is my pleasure to introduce our our first presenting company of the day, Dianthus. From the company, we have Marino Garcia, who is the Ch ...